Robert Goodnow, Ph.D.
VP, Medicinal Chemistry
Robert Goodnow is vice president of Medicinal Chemistry at Stoke Therapeutics. In this role, Robert leads efforts to identify chemical compounds that can be developed as potential new medicines for patients. Prior to joining Stoke, Robert was Vice President of Innovation Chemistry at Pharmaron. Robert’s research has focused on the implementation of several novel chemistry platform technologies, including the use of new DNA backbones as antisense agents and small molecule-targeted delivery of siRNA, for therapeutic applications in oncology, inflammation and metabolic diseases. He has authored or co-authored more than 80 scientific papers, book chapters and patent applications. Robert holds a B.S. in chemistry from Georgetown University, and has a Ph.D. in natural products organic/bioorganic chemistry from Columbia University.